Goldman Sachs’s Juno Therapeutics, Inc. JUNO Stock Holding History

Goldman Sachs’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,200	Closed	-$101K	–	6660
2017 Q4	$101K	Sell	2,200 -44,900	-95%	-$2.24M	﹤0.01%	5741
2017 Q3	$2.11M	Sell	47,100 -2,700	-5%	-$92K	﹤0.01%	3938
2017 Q2	$1.49M	Buy	49,800 +34,600	+228%	+$854K	﹤0.01%	4093
2017 Q1	$337K	Hold	15,200	–	–	﹤0.01%	5368
2016 Q4	$287K	Sell	15,200 -15,700	-51%	-$384K	﹤0.01%	5523
2016 Q3	$927K	Buy	30,900 +13,500	+78%	+$420K	﹤0.01%	4475
2016 Q2	$669K	Buy	17,400 +2,000	+13%	+$83K	﹤0.01%	4579
2016 Q1	$587K	Buy	15,400 +5,100	+50%	+$178K	﹤0.01%	4590
2015 Q4	$453K	Sell	10,300 -6,200	-38%	-$307K	﹤0.01%	5010
2015 Q3	$671K	Buy	16,500 +5,200	+46%	+$228K	﹤0.01%	4857
2015 Q2	$603K	Buy	11,300 +10,400	+1,156%	+$552K	﹤0.01%	4992
2015 Q1	$55K	Buy	+900	New	+$43.7K	﹤0.01%	6661

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Goldman Sachs's JUNO Position: Q1 2018 in Review

Goldman Sachs sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,594,770 shares — an estimated $72.9M sold.

Goldman Sachs first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $72.9M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Goldman Sachs reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Goldman Sachs sold 1,594,770 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $72.9M.
Goldman Sachs first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Goldman Sachs's Juno Therapeutics, Inc. position peaked at $72.9M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.